Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPHNASDAQ:AUPHNASDAQ:AURANASDAQ:ETNB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$24.47+1.1%$25.20$22.64▼$53.96$1.16B0.78480,046 shs548,566 shsAUPHAurinia Pharmaceuticals$8.08-2.3%$8.02$5.11▼$10.67$1.09B1.161.33 million shs2.01 million shsAURAAura Biosciences$5.89-0.8%$5.76$4.35▼$12.38$296.08M0.43210,551 shs158,183 shsETNB89bio$9.49-1.7%$7.33$4.16▼$11.84$1.39B1.231.42 million shs1.04 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals+1.12%-1.57%+3.86%-21.77%-43.70%AUPHAurinia Pharmaceuticals-2.30%-1.34%-0.12%+1.96%+46.11%AURAAura Biosciences-0.84%-1.01%+2.26%-21.57%-17.74%ETNB89bio-1.66%+21.98%+43.35%-14.31%+6.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPHAmphastar Pharmaceuticals4.2325 of 5 stars3.11.00.03.73.64.21.3AUPHAurinia Pharmaceuticals2.4472 of 5 stars3.51.00.00.02.60.81.9AURAAura Biosciences2.8314 of 5 stars3.62.00.00.03.93.30.0ETNB89bio2.7359 of 5 stars4.51.00.00.03.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 2.25Hold$32.3332.13% UpsideAUPHAurinia Pharmaceuticals 3.00Buy$11.5042.33% UpsideAURAAura Biosciences 3.25Buy$22.75286.25% UpsideETNB89bio 3.00Buy$26.43178.49% UpsideCurrent Analyst Ratings BreakdownLatest AURA, AMPH, ETNB, and AUPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$19.005/12/2025AMPHAmphastar PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$45.00 ➝ $30.005/10/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/8/2025AMPHAmphastar PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $35.004/30/2025ETNB89bioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/24/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/10/2025AMPHAmphastar PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/8/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)3/26/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$19.003/26/2025AURAAura BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/25/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$25.00(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$730.66M1.59$3.41 per share7.17$13.35 per share1.83AUPHAurinia Pharmaceuticals$247.30M4.41N/AN/A$2.63 per share3.07AURAAura BiosciencesN/AN/AN/AN/A$4.58 per shareN/AETNB89bioN/AN/AN/AN/A$5.75 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$137.54M$2.768.167.442.1921.80%26.44%11.89%8/6/2025 (Estimated)AUPHAurinia Pharmaceuticals-$78.02M$0.28N/A14.43N/A-10.23%-4.41%-3.07%8/7/2025 (Estimated)AURAAura Biosciences-$76.41M-$1.90N/AN/AN/AN/A-41.57%-36.43%N/AETNB89bio-$142.19M-$3.38N/AN/AN/AN/A-59.58%-52.21%8/4/2025 (Estimated)Latest AURA, AMPH, ETNB, and AUPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025AURAAura Biosciences-$0.47-$0.55-$0.08-$0.55N/AN/A5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/1/2025Q1 2025ETNB89bio-$0.50-$0.49+$0.01-$0.49N/AN/A3/24/2025Q4 2024AURAAura Biosciences-$0.43-$0.52-$0.09-$0.52N/AN/A3/6/2025Q4 2024ETNB89bio-$0.60-$1.02-$0.42-$1.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AAURAAura BiosciencesN/AN/AN/AN/AN/AETNB89bioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.823.432.61AUPHAurinia Pharmaceuticals0.175.605.11AURAAura BiosciencesN/A12.4712.47ETNB89bio0.0911.6611.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%AUPHAurinia Pharmaceuticals36.83%AURAAura Biosciences96.75%ETNB89bioN/AInsider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals27.50%AUPHAurinia Pharmaceuticals4.30%AURAAura Biosciences5.40%ETNB89bio2.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals1,62047.50 million35.05 millionOptionableAUPHAurinia Pharmaceuticals300135.10 million137.02 millionOptionableAURAAura Biosciences5050.27 million47.25 millionNot OptionableETNB89bio40145.98 million103.15 millionOptionableAURA, AMPH, ETNB, and AUPH HeadlinesRecent News About These CompaniesNorthern Trust Corp Increases Stake in 89bio, Inc. (NASDAQ:ETNB)May 22 at 3:07 AM | marketbeat.com89bio, Inc. (NASDAQ:ETNB) is Suvretta Capital Management LLC's 8th Largest PositionMay 19, 2025 | marketbeat.comRTW Investments LP Increases Stake in 89bio, Inc. (NASDAQ:ETNB)May 18, 2025 | marketbeat.comBNP Paribas Financial Markets Takes Position in 89bio, Inc. (NASDAQ:ETNB)May 18, 2025 | marketbeat.comDimensional Fund Advisors LP Buys New Stake in 89bio, Inc. (NASDAQ:ETNB)May 17, 2025 | marketbeat.comJanus Henderson Group PLC Boosts Stock Holdings in 89bio, Inc. (NASDAQ:ETNB)May 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Has $7.82 Million Holdings in 89bio, Inc. (NASDAQ:ETNB)May 14, 2025 | marketbeat.comIs Now the Time to Buy Biotech Stocks?May 13, 2025 | finance.yahoo.comWhy 89bio, Inc. (ETNB) Is Among the Best Low Priced Biotech Stocks to Buy NowMay 13, 2025 | insidermonkey.comBalyasny Asset Management L.P. Purchases Shares of 1,019,449 89bio, Inc. (NASDAQ:ETNB)May 12, 2025 | marketbeat.comAlgert Global LLC Boosts Stock Position in 89bio, Inc. (NASDAQ:ETNB)May 12, 2025 | marketbeat.comWeiss Ratings Reaffirms "Sell (D-)" Rating for 89bio (NASDAQ:ETNB)May 12, 2025 | marketbeat.com89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 9, 2025 | globenewswire.comDeep Track Capital LP Buys 3,711,737 Shares of 89bio, Inc. (NASDAQ:ETNB)May 9, 2025 | marketbeat.com89bio, Inc. (NASDAQ:ETNB) Shares Purchased by Alyeska Investment Group L.P.May 8, 2025 | marketbeat.com89bio, Inc. (NASDAQ:ETNB) Given Average Recommendation of "Buy" by BrokeragesMay 8, 2025 | marketbeat.com89bio to Participate in Upcoming Investor ConferencesMay 6, 2025 | globenewswire.com89bio, Inc. (NASDAQ:ETNB) Shares Sold by BVF Inc. ILMay 6, 2025 | marketbeat.com60,992 Shares in 89bio, Inc. (NASDAQ:ETNB) Purchased by Susquehanna Fundamental Investments LLCMay 6, 2025 | marketbeat.com89bio (NASDAQ:ETNB) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSMay 5, 2025 | marketbeat.comEquities Analysts Issue Forecasts for 89bio FY2025 EarningsMay 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAURA, AMPH, ETNB, and AUPH Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$24.47 +0.27 (+1.12%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$24.09 -0.38 (-1.54%) As of 05/23/2025 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Aurinia Pharmaceuticals NASDAQ:AUPH$8.08 -0.19 (-2.30%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$8.12 +0.04 (+0.56%) As of 05/23/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Aura Biosciences NASDAQ:AURA$5.89 -0.05 (-0.84%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.94 +0.05 (+0.85%) As of 05/23/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.89bio NASDAQ:ETNB$9.49 -0.16 (-1.66%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$9.68 +0.19 (+1.96%) As of 05/23/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
